- Home
- NGL vs ZYME Comparison
NGL vs ZYME Comparison
Compare NGL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGL
- ZYME
- Stock Information
- Founded
- NGL 1940
- ZYME 2003
- Country
- NGL United States
- ZYME United States
- Employees
- NGL N/A
- ZYME N/A
- Industry
- NGL Natural Gas Distribution
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- NGL Utilities
- ZYME Health Care
- Exchange
- NGL Nasdaq
- ZYME Nasdaq
- Market Cap
- NGL 645.5M
- ZYME 765.3M
- IPO Year
- NGL 2011
- ZYME 2017
- Fundamental
- Price
- NGL $3.01
- ZYME $12.44
- Analyst Decision
- NGL
- ZYME Buy
- Analyst Count
- NGL 0
- ZYME 6
- Target Price
- NGL N/A
- ZYME $19.50
- AVG Volume (30 Days)
- NGL 680.3K
- ZYME 825.0K
- Earning Date
- NGL 06-05-2025
- ZYME 05-08-2025
- Dividend Yield
- NGL N/A
- ZYME N/A
- EPS Growth
- NGL N/A
- ZYME N/A
- EPS
- NGL N/A
- ZYME N/A
- Revenue
- NGL $5,918,601,000.00
- ZYME $76,304,000.00
- Revenue This Year
- NGL N/A
- ZYME $26.29
- Revenue Next Year
- NGL N/A
- ZYME $75.78
- P/E Ratio
- NGL N/A
- ZYME N/A
- Revenue Growth
- NGL N/A
- ZYME 0.38
- 52 Week Low
- NGL $2.64
- ZYME $7.97
- 52 Week High
- NGL $6.08
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- NGL 34.64
- ZYME 59.19
- Support Level
- NGL $2.80
- ZYME $10.69
- Resistance Level
- NGL $3.03
- ZYME $11.48
- Average True Range (ATR)
- NGL 0.34
- ZYME 0.81
- MACD
- NGL -0.03
- ZYME 0.27
- Stochastic Oscillator
- NGL 23.38
- ZYME 92.79
About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, and for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.